Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Clin Cancer Res (2020) 26 (2): 364–372.

https://doi.org/10.1158/1078-0432.CCR-18-3965

Published: 15 January 2020

View article titled, Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Includes: Supplementary data

Journal Articles

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

David J. Stewart, Gerald Batist, Hagop M. Kantarjian, John-Peter Bradford, Joan H. Schiller, Razelle Kurzrock

Clin Cancer Res (2015) 21 (20): 4561–4568.

https://doi.org/10.1158/1078-0432.CCR-14-3246

Published: 14 October 2015

View article titled, The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

Journal Articles

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Brian I. Rini, Joan H. Schiller, John P. Fruehauf, Ezra E.W. Cohen, Jamal C. Tarazi, Brad Rosbrook, Angel H. Bair, Alejandro D. Ricart, Anthony J. Olszanski, Kristen J. Letrent, Sinil Kim, Olivier Rixe

Clin Cancer Res (2011) 17 (11): 3841–3849.

https://doi.org/10.1158/1078-0432.CCR-10-2806

Published: 01 June 2011

View article titled, Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Journal Articles

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Afshin Dowlati, Robert Gray, Alan B. Sandler, Joan H. Schiller, David H. Johnson

Clin Cancer Res (2008) 14 (5): 1407–1412.

https://doi.org/10.1158/1078-0432.CCR-07-1154

Published: 03 March 2008

View article titled, Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Includes: Supplementary data

Journal Articles

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Roy S. Herbst, Angela M. Davies, Ronald B. Natale, Thao P. Dang, Joan H. Schiller, Linda L. Garland, Vincent A. Miller, David Mendelson, Annick D. Van den Abbeele, Yulia Melenevsky, Daniel J. de Vries, David A. Eberhard, Benjamin Lyons, Stuart G. Lutzker, Bruce E. Johnson

Clin Cancer Res (2007) 13 (20): 6175–6181.

https://doi.org/10.1158/1078-0432.CCR-07-0460

Published: 18 October 2007

View article titled, Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Journal Articles

Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

Gregory A. Otterson, Miguel A. Villalona-Calero, Sunil Sharma, Mark G. Kris, Anthony Imondi, Mirjam Gerber, Dorothy A. White, Mark J. Ratain, Joan H. Schiller, Alan Sandler, Michael Kraut, Sridhar Mani, John R. Murren

Clin Cancer Res (2007) 13 (4): 1246–1252.

https://doi.org/10.1158/1078-0432.CCR-06-1096

Published: 22 February 2007

View article titled, Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

Journal Articles

Study Design Issues and Early Stage Non–Small Cell Lung Cancer

Joan H. Schiller

Clin Cancer Res (2005) 11 (13): 5030s–5032s.

https://doi.org/10.1158/1078-0432.CCR-05-9003

Published: 06 July 2005

View article titled, Study Design Issues and Early Stage Non–Small Cell Lung Cancer

Journal Articles

Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement

Thomas J. Lynch, Jeffrey A. Bogart, Walter J. Curran, Jr, Malcolm M. DeCamp, David R. Gandara, Glenwood Goss, Claudia I. Henschke, James R. Jett, Bruce E. Johnson, Karen L. Kelly, Thierry Le Chevalier, James L. Mulshine, Giorgio V. Scagliotti, Joan H. Schiller, Alice Shaw, Nick Thatcher, Everett E. Vokes, Douglas E. Wood, Carol Hart

Clin Cancer Res (2005) 11 (13): 4981s–4983s.

https://doi.org/10.1158/1078-0432.CCR-05-9015

Published: 06 July 2005

View article titled, Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement

Journal Articles

Clinical Trial Design Issues in the Era of Targeted Therapies

Joan H. Schiller

Clin Cancer Res (2004) 10 (12): 4281s–4282s.

https://doi.org/10.1158/1078-0432.CCR-040008

Published: 15 June 2004

View article titled, Clinical Trial Design Issues in the Era of Targeted Therapies

Journal Articles

Novel Agents in the Treatment of Lung Cancer: Conference Summary Statement

Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Raymond N. DuBois, David R. Gandara, Giuseppe Giaccone, Ramaswamy Govindan, Roy S. Herbst, Bruce E. Johnson, Fadlo R. Khuri, Roman Perez-Soler, Rafael Rosell, Eric K. Rowinsky, Alan B. Sandler, Giorgio V. Scagliotti, Joan H. Schiller, Geoffrey I. Shapiro, Mark A. Socinski, Carol S. Hart

Clin Cancer Res (2004) 10 (12): 4199s–4204s.

https://doi.org/10.1158/1078-0432.CCR-040021

Published: 15 June 2004

View article titled, Novel Agents in the Treatment of Lung Cancer: <subtitle>Conference Summary Statement</subtitle>

Journal Articles

A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer

Roy S. Herbst, Lisa A. Hammond, David P. Carbone, Hai T. Tran, Kenneth J. Holroyd, Avinash Desai, Jon I. Williams, B. Nebiyou Bekele, Howard Hait, Victoria Allgood, Stephen Solomon, Joan H. Schiller

Clin Cancer Res (2003) 9 (11): 4108–4115.

Published: 30 September 2003

View article titled, A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer

Journal Articles

A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer

C. Casey Cunningham, Jon T. Holmlund, Joan H. Schiller, Richard S. Geary, T. Jesse Kwoh, Andrew Dorr, John Nemunaitis

Clin Cancer Res (2000) 6 (5): 1626–1631.

Published: 01 May 2000

View article titled, A Phase I Trial of c-<em>Raf</em> Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer

Journal Articles

Potentiation of Platinum Antitumor Effects in Human Lung Tumor Xenografts by the Angiogenesis Inhibitor Squalamine: Effects on Tumor Neovascularization

Joan H. Schiller, Gerard Bittner

Clin Cancer Res (1999) 5 (12): 4287–4294.

Published: 01 December 1999

View article titled, Potentiation of Platinum Antitumor Effects in Human Lung Tumor Xenografts by the Angiogenesis Inhibitor Squalamine: <subtitle>Effects on Tumor Neovascularization</subtitle>

Journal Articles

Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations

Jacquelyn A. Hank, Jean Surfus, Jacek Gan, Mark Albertini, Mary Lindstrom, Joan H. Schiller, Kirsten M. Hotton, Masoud Khorsand, Paul M. Sondel

Clin Cancer Res (1999) 5 (2): 281–289.

Published: 01 February 1999

View article titled, Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations

NARROW

Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

Study Design Issues and Early Stage Non–Small Cell Lung Cancer

Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement

Clinical Trial Design Issues in the Era of Targeted Therapies

Novel Agents in the Treatment of Lung Cancer: Conference Summary Statement

A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer

A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer

Potentiation of Platinum Antitumor Effects in Human Lung Tumor Xenografts by the Angiogenesis Inhibitor Squalamine: Effects on Tumor Neovascularization

Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only